Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, BioGend Therapeutics Co's PEG is 1. BioGend Therapeutics Co's 5-Year TTM EBITDA Growth Rate is 22.64.
BioGend Therapeutics Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-0.54. Therefore, the Peter Lynch Fair Value for today is NT$-12.32.
The historical rank and industry rank for BioGend Therapeutics Co's Peter Lynch Fair Value or its related term are showing as below:
ROCO:6733's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.19 * Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
BioGend Therapeutics Co (ROCO:6733) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 22.64 instead of 15 in this case.
BioGend Therapeutics Co's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
27.10
/
-12.32
=
N/A
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co Peter Lynch Fair Value Related Terms
BioGend Therapeutics Co Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for BioGend Therapeutics Co's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co Peter Lynch Fair Value Chart
ROCO:6733 vs VRTX, REGN, RVMD: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Price-to-Peter-Lynch-Fair-Value falls into.
BioGend Therapeutics Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of NT$-12.32 mean?
BioGend Therapeutics Co (ROCO:6733) has a Peter Lynch Fair Value of NT$-12.32 as of Aug. 09, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BioGend Therapeutics Co and its competitors. According to the industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 47 companies in the Biotechnology industry.
Is BioGend Therapeutics Co's Peter Lynch Fair Value too high?
BioGend Therapeutics Co's current Peter Lynch Fair Value is NT$-12.32. Based on the distribution chart, BioGend Therapeutics Co ranks #999999 out of 47 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Peter Lynch Fair Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 47 companies for Peter Lynch Fair Value. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.19, based on 47 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Peter Lynch Fair Value is NT$-12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$56.35, compared to a current price of NT$27.10 — trading 51.9% below its estimated fair value. The current Peter Lynch Fair Value is NT$-12.32. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Peter Lynch Fair Value is NT$-12.32 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$27.10 is trading 51.9% below its estimated GF Value™ of NT$56.35.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Peter Lynch Fair Value: NT$-12.32
GF Value™: NT$56.35 vs. price of NT$27.10 (51.9% below fair value)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
